All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Sylvester Selected to Join AACR’s Worldwide Data-Sharing Registry

May 15th 2023

The American Association for Cancer Research has selected Sylvester Comprehensive Cancer Center as one of the newest members of a worldwide consortium contributing genomic data to AACR’s Project GENIE.

ECLIPSE PV Trial Begins Ropeginterferon Alfa-2b Dosing in Polycythemia Vera

May 15th 2023

The first patients have been dosed in the phase 3b ECLIPSE PV trial, which is evaluating an accelerated dosing schedule of ropeginterferon alfa-2b-njft for the treatment of patients with polycythemia vera.

The Future of Reimbursement: How AI Can Revolutionize Oncology Practices

May 15th 2023

By retrospectively analyzing health care financial data and using the intelligence generated to guide future claims to a more successful outcome, machine learning platforms may reduce the need for repeated insurance submissions and appeals and can improve the practice’s clean claim rate.

Capivasertib Plus Fulvestrant Provides Consistent PFS Benefit in HR+ Advanced Breast Cancer, Across Key Subgroups

May 15th 2023

Capivasertib plus fulvestrant provided a clinically meaningful improvement in progression-free survival over fulvestrant alone in patients with hormone receptor–positive advanced breast cancer, including those who previously received a CDK4/6 inhibitor, chemotherapy in the advanced setting, or had baseline liver metastases.

OP-1250 Plus Palbociclib Demonstrates Activity, Safety in HR+/HER2– Metastatic Breast Cancer

May 14th 2023

The combination of OP-1250 and palbociclib produced a tolerable safety profile and elicited tumor responses and disease stabilization in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

MONALEESA-2 Subgroup Analysis Highlights Survival Benefit With Ribociclib/Letrozole in HR+ Breast Cancer

May 13th 2023

The frontline combination of ribociclib and letrozole significantly prolonged overall survival over letrozole alone in a subset of patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy, according to data from an exploratory analysis of the phase 3 MONALEESA-2 trial.

Neoadjuvant Atezolizumab/Epirubicin Plus Trastuzumab/Pertuzumab Shows High pCR Rate in Early HER2+ Breast Cancer

May 12th 2023

Preoperative treatment with atezolizumab, epirubicin, trastuzumab, and pertuzumab led to improved rates of pathologic complete response and decreased residual cancer burden compared with trastuzumab, pertuzumab, and chemotherapy alone in patients with early-stage HER2-positive breast cancer, according to findings from the randomized phase 2 ATHENE trial.

mRNA Vaccine Autogene Cevumeran Plus Atezolizumab and Chemotherapy Displays Early Efficacy in PDAC

May 12th 2023

Adjuvant treatment with the individualized RNA neoantigen vaccine autogene cevumeran in combination with atezolizumab and chemotherapy induced notable T-cell activity that could be correlated with delayed recurrence in patients with pancreatic ductal adenocarcinoma.

Neoadjuvant Atezolizumab Plus Chemotherapy Numerically Improves Survival in Early TNBC

May 12th 2023

The addition of atezolizumab to neoadjuvant chemotherapy generated numerical improvements in event-free survival, disease-free survival, and overall survival compared with chemotherapy plus placebo in patients with early-stage triple-negative breast cancer.

Sacituzumab Govitecan Produces Consistent Clinical Outcomes in mTNBC, Irrespective of Neutropenia and Diarrhea AEs

May 12th 2023

Sacituzumab govitecan-hziy produced comparable efficacy outcomes for patients with metastatic triple-negative breast cancer who had a higher incidence of grade 2 or 3 diarrhea and neutropenia vs patients in the overall population, according to a post hoc analysis of the phase 3 ASCENT trial presented at the 2023 ESMO Breast Cancer Annual Congress.

ER-low Expressors Experience Benefit With Trastuzumab Deruxtecan in DESTINY-Breast04 Subgroup Analysis

May 12th 2023

Fam-trastuzumab deruxtecan-nxki was associated with better efficacy outcomes compared with treatment of physician’s choice in patients with HER2-low, estrogen receptor-low metastatic breast cancer, according to findings from a subgroup analysis of the phase 3 DESTINY-Breast04 study.

Trilaciclib Prior to Sacituzumab Govitecan Shows Early Potential in Metastatic TNBC

May 12th 2023

Administration of trilaciclib followed by sacituzumab govitecan showed early signals of efficacy and may reduce the incidence of adverse effects in heavily pretreated patients with unresectable locally advanced or metastatic triple-negative breast cancer, according to preliminary results from a phase 2 study.

Lewis Katz School of Medicine’s Dr. Matthew Lee Discusses Experience With New Robotic Laparoscopic Procedure at 2023 AUA Annual Meeting

May 12th 2023

Matthew Lee, MD, MBA, discusses his use of a new robotic laparoscopic procedure to treat a complication caused by cancer radiation therapy at the 2023 American Urological Association Annual Meeting.

PYX-201 Receives Orphan Drug Designation From the FDA in Pancreatic Cancer

May 12th 2023

The FDA has granted an orphan drug designation to PYX-201 for the treatment of patients with pancreatic cancer.

Hormonal Maintenance Therapy Offers Deescalated Option for Low-Grade Serous Ovarian Cancers

May 12th 2023

Patients with low-grade serous ovarian carcinoma historically have demonstrated a benefit with hormonal maintenance therapy following cytoreductive surgery and platinum-based chemotherapy.

Hsp70 Inhibition Could Help Overcome Belzutifan Resistance in VHL Disease–Associated ccRCC

May 12th 2023

Michael Basin, MD, discusses the rationale for the preclinical investigation of belzutifan resistance in ccRCC cell lines, the next steps for this research, and the potential implications for combining Hsp70 inhibition with a HIF2α inhibitor.

Post-Hoc Analysis Shows Olaparib Maintains PFS Benefit in gBRCA+ HER2– Metastatic Breast Cancer, Irrespective of ER Expression

May 11th 2023

Olaparib provided consistent clinical benefit in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer, irrespective of estrogen receptor expression level.

Abemaciclib Is Associated With a Manageable Safety Profile in Early HR+/HER2- Breast Cancer

May 11th 2023

Adjuvant abemaciclib with endocrine therapy led to a tolerable safety profile in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer,

Trastuzumab Deruxtecan Elicits Superior HRQOL in HER2+ Metastatic Breast Cancer

May 11th 2023

Patient-reported outcomes with fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer reflected the regimen’s favorable risk-benefit profile in the phase 3 DESTINY-Breast02 trial, according to findings presented during the 2023 ESMO Breast Cancer Annual Congress.

Toxicity Profile With Trastuzumab Deruxtecan Proves Consistent, Manageable in HER2-Low Metastatic Breast Cancer

May 11th 2023

Treatment with trastuzumab deruxtecan resulted in lower exposure-adjusted incidence rates per patient-year of treatment-emergent adverse effects compared with treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer, according to safety analysis from the phase 3 DESTINY-Breast04 trial.